Psilocybin for OCD: Terence Ching on Lessons from Yale’s Randomised Trials By Watertime - March 12, 2026 2 Post Content RELATED ARTICLESMORE FROM AUTHOR Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions
